Currently available agents for erectile dysfunction (ED) share the same mechanism of action and pharmacologic properties. Therefore, they share the same limitations, including a principal focus on erection as an end-organ process. One of the relatively unexplored areas of research has been the potential for centrally acting agents to improve male sexual response. A variety of neurohormones and neurotransmitter systems are involved in the male sexual response, including testosterone, dopamine, serotonin and the melanocortin systems. Investigations to determine the utility of centrally acting agents as monotherapy or adjunctive therapy in men with ED or other forms of sexual dysfunction are underway. Bremelanotide, a melanocortin agonist, has been tested in men with ED and may prove to be one of the first centrally acting agents to have clinical utility in male sexual dysfunction.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Basic and Clinical Andrology Open Access 09 June 2011
Subscribe to Journal
Get full journal access for 1 year
only $14.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA et al. Oral sildenafil in the treatment of erectile dysfunction. N Eng J Med 1998; 338: 1397–1404.
Raina R, Lakin ML, Agarwal A, Sharma R, Goyal KK, Montague DK et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003; 62: 110–115.
Viagra [package insert]. Pfizer Labs: New York NY, 2006.
Levitra [package insert]. Bayer Pharmaceuticals Corporation: West Haven CT, 2007.
Cialis [package insert]. Lilly ICOS LLC: Indianapolis IN, 2003.
Kendirci M, Walls MM, Hellstrom WJ . Central nervous system agents in the treatment of erectile dysfunction. Urol Clin N Am 2005; 32: 487–501.
Ojumu A, Dobs AS . Is hypogonadism a risk factor for sexual dysfunction? J Androl 2003; 24: S46–S51.
Carani C, Bancroft J, Del Rio G, Granata AR, Facchinetti F, Marrama P . The endocrine effects of visual erotic stimuli in normal men. Psychoneuroendocrinology 1990; 15: 207–216.
Seftel A . Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2007; 19: 2–24.
Schubert M, Jockenhovel F . Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. J Endocrinol Invest 2005; 28 (3 Suppl): 23–27.
Rhoden EL, Morgataler A . Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492.
Haren MT, Kim MJ, Tariq SH, Wittert GA, Morley JE . Andropause: a quality-of-life issue in older males. Med Clin North Am 2006; 90: 1005–1023.
Lazarou S, Morgentaler A . Hypogonadism in the man with erectile dysfunction: what to look for and when to treat. Curr Urol Rep 2005; 6: 476–481.
Bancroft J . The endocrinology of sexual arousal. J Endocrin 2005; 186: 411–427.
Scepkowski LA, Georgescu M, Pfaus JG . Neuroendocrine factors in sexual desire and motivation. In: Goldstein I, Traish A, Davis S, Meston C (eds). Women's Sexual Function and Dysfunction. Taylor & Francis Ltd: London, 2005, pp 159–168.
O′Carroll R, Bancroft J . Testosterone therapy for low sexual interest and erectile dysfunction in men: a controlled study. Br J Psychiatry 1984; 145: 146–151.
Frajese G, Lazzari R, Magnani A, Moretti C, Sforza V, Nerozzi D . Neurotransmitter, opiodergic system, steroid-hormone interaction and involvement in the replacement therapy of sexual disorders. J Steroid Biochem Mol Biol 1990; 37: 411–419.
Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxford) 2005; 63: 381–394.
Both S, Everaerd W, Laan E, Gooren L . Effect of a single dose of levodopa on sexual response in men and women. Neuropsychopharmacology 2005; 30: 173–183.
Lal S, Ackman D, Thavundayil JX, Kiely ME, Etienne P . Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 695–699.
Heaton JP, Morales A, Adams MA, Johnston B, el-Rashidy R . Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200–206.
Mirone VG, Stief CG . Efficacy of apomorphine SL in erectile dysfunction. BJU Int 2001; 88 (s3): 25–29.
Dula E, Bukofzer S, Perdok R, George M, the Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558–564.
Broderick GA . Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. Rev Urol 2003; 5 (Suppl 7): S9–S20.
Perimenis P, Markou S, Gyftopoulos K, Giannitsas K, Athanasopoulos A, Liatsikos E et al. Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Andrologia 2004; 36: 106–110.
Perimenis P, Gyftopoulos K, Giannitsas K, Markou SA, Tsota I, Chrysanthopoulou A et al. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res 2004; 16: 2–7.
Eardley I, Wright P, MacDonagh R, Hole J, Edwards A . An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine in men with erectile dysfunction. Andrology 2004; 93: 1271–1275.
Porst H, Bebre HM, Jungwirth A, Burkart M . Comparative trial of treatment satisfaction, efficacy, and tolerability of sildenafil versus apomorphine in erectile dysfunction. An open, randomized cross-over study with flexible dosing. Eur J Med Res 2007; 12: 61–67.
Maggi I, Filippi S, Ledda F, Magini A, Forti G . Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol 2000; 143: 143–154.
Ernst E, Pittler MH . Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159: 433–436.
Uckert S, Fuhlenriede MH, Becker AJ, Stief CG, Scheller F, Knapp WH et al. Is serotonin significant for the control of penile flaccidity and detumescence in the human male? Urol Res 2003; 31: 55–60.
Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357–366.
Rosen RC, Lane RM, Menza M . Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19: 67–85.
Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003; 28: 413–420.
Waldinger MD . The neurobiological approach to premature ejaculation. J Urol 2002; 168: 2359–2367.
Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A et al. ‘Dopamine-dependent’ side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 2004; 65: 1064–1068.
Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB . Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006; 59: 203–210.
Clayton A, Keller A, McGarvey EL . Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006; 9: 27–32.
Masand PS, Ashton AK, Gupta S, Frank B . Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry 2001; 158: 805–807.
Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006; 67: 736–746.
DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E . A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005; 66: 844–848.
Taylor MJ . Strategies for managing antidepressant-induced sexual dysfunction: a review. Curr Psychiatry Rep 2006; 8: 431–436.
Voisey J, Carroll L, van Daal A . Melanocortins and their receptors and antagonists. Curr Drug Targets 2003; 4: 586–597.
Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X et al. A role for the melanocortin 4 receptor in sexual function. Proc Nat Acad Sci 2002; 99: 11381–11386.
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB . Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004; 16: 135–142.
Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB . Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16: 51–59.
Diamond LE, Earle DC, Garcia WD, Spana C . Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology 2005; 65: 755–759.
Kaminetsky J, Zinner N, Gittleman M, Auerbach S, Fischkoff S . Phase IIb study of bremelanotide in the treatment of ED in non-diabetic males. Proceedings of the American Urology Association Annual Meeting; 19–24 May 2007; Anaheim, USA.
Althof SE, Pereman MA, Rosen RC, Fischkoff S, Earle D . Improvement in sexual relationship satisfaction, confidence, and self-esteem in erectile dysfunction patients treated with bremelanotide. Proceedings of the American Urology Association Annual Meeting; 19–24 May 2007; Anaheim, USA.
Hellstrom WJ, Gittelman M, Zinner N, Hallam T, Harning R, Dworaczyk DA et al. Randomized, double-blind, placebo-controlled, at-home study to evaluate the efficacy and safety of intranasal bremelanotide in men with erectile dysfunction with and without diabetes mellitus. Proceedings of the European Society for Sexual Medicine (ESSM) Annual Meeting; 3–6 December 2006; Vienna, Austria.
Diamond LE, Earle DC, Heiman JC, Rosen RC, Perelman MA, Harning R . An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006; 3: 628–638.
This work was supported by a grant from Palatin Technologies, Inc. Editorial support for the development of this paper was provided by Kevin Kehres.
Dr Hellstrom serves as a consultant/advisor, lecturer and/or clinical trial investigator for the following: VIVUS, Mentor, Bayer, Pfizer, Johnson & Johnson, Auxilium, King, Palatin, American Medical Systems, Medtronic, GlaxoSmithKline, Coloplast and Sanofi-Synthelabo.
About this article
Cite this article
Hellstrom, W. Clinical applications of centrally acting agents in male sexual dysfunction. Int J Impot Res 20 (Suppl 1), S17–S23 (2008). https://doi.org/10.1038/ijir.2008.18
- male sexual dysfunction
- erectile dysfunction
This article is cited by
Basic and Clinical Andrology (2011)
Yohimbine relaxes the human corpus cavernosum through a non-adrenergic mechanism involving the activation of K+ATP-dependent channels
International Journal of Impotence Research (2009)